



May 30, 2014

Press release

Mitsubishi Tanabe Pharma Corporation

Name Change of Group Company in China

Osaka, Japan, May 30, 2014---Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Michihiro Tsuchiya) announced today that one of the consolidated subsidiaries in China, Mitsubishi Pharma Research & Development (Beijing) Co., Ltd. (Head office: Beijing, China, Chairman & Managing Director: Yoshikazu Kobayashi), will change its name to Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd., effective June 1, 2014.

Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd. has been carried out clinical development for acquiring regulatory approval for pharmaceutical sales in China since 2006.

Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd., as the Group's key base in China, will promote business development in China through new drug development and acquisition of regulatory approval, and thereby aim to raise the value of the company.

Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd.

Head office: Room No.1605, 1606, 1607A, 16F Office Building F, Phoenix Place, Tower 21, No.A5,
Shuguangxili, Chaoyang District, Beijing, China

President & CEO: Yoshikazu Kobayashi

Capital stock: USD1 million

Shareholder: Mitsubishi Tanabe Pharma Corporation (100%)

<Contact for Inquiries>

Corporate Communications Department

Phone: +81 6-6205-5211